TABLE 1.
Baseline characteristics of HIV-infected adult men and nonpregnant women with insufficient serum 25(OH)D concentrations (<30 ng/mL) at ART initiation enrolled in the trial, by vitamin D3 and placebo treatment groups1
| Vitamin D3 (n = 2001) | Placebo (n = 1999) | |
|---|---|---|
| Sex | ||
| Female | 1367 (68) | 1368 (68) |
| Male | 634 (32) | 631 (32) |
| Age, y | 38.6 ± 9.8 | 38.8 ± 10.0 |
| Education | ||
| No formal education | 308 (15) | 327 (16) |
| Primary | 1294 (64) | 1294 (65) |
| Secondary/advanced | 398 (20) | 377 (19) |
| BMI, kg/m2 | ||
| <18.5 | 440 (22) | 404 (20) |
| 18.5–24.9 | 1038 (52) | 1064 (53) |
| ≥25.0 | 521 (26) | 531 (27) |
| CD4 T-cell count, cells/μL | ||
| <200 | 866 (43) | 845 (42) |
| 200–349 | 461 (23) | 445 (22) |
| 350–499 | 300 (15) | 333 (17) |
| ≥500 | 284 (14) | 178 (14) |
| Missing | 90 (5) | 98 (5) |
| WHO HIV disease stage | ||
| I/II | 744 (37) | 760 (38) |
| III | 1161 (58) | 1143 (57) |
| IV | 96 (5) | 96 (5) |
| Baseline pulmonary tuberculosis | 189 (10) | 175 (9) |
| HSCL-25 score consistent with depression | 982 (49) | 953 (48) |
| ART regimen | ||
| Efavirenz/lamivudine/tenofovir | 1940 (97) | 1943 (97) |
| Other ART regimen | 61 (3) | 56 (3) |
| 25(OH)D concentrations at screening visit, ng/mL | ||
| Insufficient (20.0–30.0) | 955 (48) | 972 (49) |
| Moderate deficiency (10.0–19.9) | 920 (46) | 865 (43) |
| Severe deficiency (0–9.9) | 126 (6) | 162 (8) |
1
n = 4000. Values are n (%) or mean ± SD. ART, antiretroviral therapy; HSCL-25, Hopkins Symptom Checklist-25; vitamin D3, cholecalciferol; 25(OH)D, 25-hydroxyvitamin D.